Parabilis Medicines (PBLS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.52B and a free-cash-flow yield of -4.2%. Nama's AI scorecard rates it Sell, 3.0 out of 10.
AI scorecard
Sell · 3.0/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-32.8%
How far the last close sits under the highest price of the past five years.
Market cap
$3.52B
Trailing P/E
—
Price / book
3.4
Price / sales
—
FCF yield
-4.2%
Dividend yield
—
Gross margin
0.0%
Operating margin
-34382.4%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
PBLS earnings
Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$0.38).
Beat the EPS estimate in 0 of 1 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 13, 2026
-$2.12
-$0.24
-783.3%
$148,000
PBLS analyst price target
Median target $40.00 from 5 analysts, ranging $40.00 – $45.00.
Nama's AI scorecard currently rates Parabilis Medicines Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PBLS report earnings?
Parabilis Medicines's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.38.
What is the PBLS price target?
The median analyst price target from 5 analysts is $40.00, with a range of $40.00 – $45.00.
Is PBLS Shariah compliant?
Nama's AAOIFI-style screen reads Parabilis Medicines as Not Shariah Compliant. At least one of the three ratios or the industry test failed.